Current and historical debt to equity ratio values for Microbot Medical (MBOT) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Microbot Medical debt/equity for the three months ending March 31, 2019 was 0.03.
Track your investing performance and net worth with the highly rated free tool from Personal Capital. The New York Times said "When it comes to managing your investments, Personal Capital is the tool to beat."
Microbot Medical Debt/Equity Ratio Historical Data
Microbot Medical Inc. is engaged in the research, design, development and commercialization of micro-robotics assisted medical technologies. Its product candidate includes the Self Cleaning Shunt for the treatment of hydrocephalus and Normal Pressure Hydrocephalus and TipCAT, a self-propelling, semi-disposable endoscope which is being developed initially for use in colonoscopy procedures. Microbot Medical Inc., formerly known as Stemcells, Inc., is headquartered in Hingham, MA.